The Christopher & Dana Reeve Foundation and Spinal Research have partnered to fund pre-clinical research applications on paralysis caused by traumatic spinal cord injury in support of the mission of both organizations.
A downloadable PDF of the Pre-clinical Request for Applications Overview & Guide is available here as a PDF. Visit the portal to access and review the guide in full.
Request for Application (RFA) Overview
A critical step in the translational pipeline is that between discovery and Investigational New Drug (or Investigational Device) enabling studies. Therefore, this request for applications (RFA) encompasses early pre-clinical (non-human) to translational research to support pre-IND or pre-IDE studies in traumatic spinal cord injury (SCI).
Our goal is to promote an understanding of a proposed therapeutic that will encourage continued engagement and support to prepare for the next stages of scientific research and development. Studies of new or repurposed drugs and biologics, and non-clinical research for medical devices, gene therapy approaches, of neuroprotection, regeneration and plasticity are within the scope of the RFA. Full drug screens, IND enabling studies or clinical research are outside the scope of this RFA.
Deadlines
Please note: Applicants are encouraged to apply early in the event of issues with the submission process. Program staff will be unable to respond to queries in the two days prior to an application deadline; all queries must be sent prior to that time. Please do not request updates from program staff prior to timelines delineated above.
This RFA supports pre-clinical (non-human) research of new or repurposed drugs and biologics in the areas of neuroprotection, regeneration and plasticity, at the pre-IND or pre-IDE development stage.
This RFA will be a two-stage process with an initial LOI submissions and review, followed for an invitation only full grant application process.
